NCT05218356: Phase IIa Randomized Placebo Controlled Clinical Study of Codivir in Hospitalized Patients with Moderate COVID-19 |
|
|
| Recruiting | 2 | 130 | RoW | Covidir injections, Experimental drug administration, Quantitative PCR SARS-CoV-2, IgM and IgG dosage, Screening Blood tests, Electrocardiogram, ECG, NEWS-2 score, WHO score, Physical examination, COVID-19-Related Symptoms assessment | Code Pharma | COVID-19 | 12/24 | 07/25 | | |
